%PDF-1.6
%
1 0 obj
<>
endobj
2 0 obj
<>stream
2016-09-05T12:59:14+01:00
2016-09-05T12:59:14+01:00
2016-09-05T12:59:14+01:00
Adobe Acrobat 10.0
application/pdf
D:\absmgr cd's\DGHO2016\Texte\ABS00730.htm
uuid:818d3f52-bac5-4ac5-b6b2-05816f3ac3e7
uuid:ad0e575d-640d-48fa-84d6-725c216c84da
Acrobat Web Capture 10.0
endstream
endobj
5 0 obj
<>
endobj
6 0 obj
<>
endobj
3 0 obj
<>
endobj
7 0 obj
<>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC]/XObject<>>>/Type/Page>>
endobj
11 0 obj
[23 0 R 24 0 R]
endobj
12 0 obj
<>stream
/CS0 cs 1 scn
57 57 572.251 771 re
f
63 744 560.25 -11.25 re
f
0.604 scn
q 1 0 0 1 64.5003 738.7497 cm
0 0 m
0.75 -0.75 l
556.5 -0.75 l
557.249 0 l
h
f
Q
0.933 scn
q 1 0 0 1 64.5003 738 cm
0 0 m
0.75 0 l
556.5 0 l
557.249 0 l
h
f
Q
0.604 scn
q 1 0 0 1 64.5003 738 cm
0 0 m
0.75 0 l
0 0.75 l
h
f
Q
0.933 scn
q 1 0 0 1 621 738 cm
0 0 m
0.75 0 l
0.75 0.75 l
h
f
Q
0.8 scn
63 701.25 560.25 -39 re
f
1 scn
63 662.25 560.25 -30 re
f
0.8 scn
63 632.25 560.25 -60 re
f
1 scn
63 572.25 560.25 -267 re
f
63 305.25 560.25 -27 re
f
0.604 scn
q 1 0 0 1 64.5003 270.7497 cm
0 0 m
0.75 -0.75 l
556.5 -0.75 l
557.249 0 l
h
f
Q
0.933 scn
q 1 0 0 1 64.5003 270 cm
0 0 m
0.75 0 l
556.5 0 l
557.249 0 l
h
f
Q
0.604 scn
q 1 0 0 1 64.5003 270 cm
0 0 m
0.75 0 l
0 0.75 l
h
f
Q
0.933 scn
q 1 0 0 1 621 270 cm
0 0 m
0.75 0 l
0.75 0.75 l
h
f
Q
0.604 scn
q 1 0 0 1 64.5003 171 cm
0 0 m
0.75 -0.75 l
556.5 -0.75 l
557.249 0 l
h
f
Q
0.933 scn
q 1 0 0 1 64.5003 170.2503 cm
0 0 m
0.75 0 l
556.5 0 l
557.249 0 l
h
f
Q
0.604 scn
q 1 0 0 1 64.5003 170.2503 cm
0 0 m
0.75 0 l
0 0.75 l
h
f
Q
0.933 scn
q 1 0 0 1 621 170.2503 cm
0 0 m
0.75 0 l
0.75 0.75 l
h
f
Q
q
64.5 745.5 563.25 75.001 re
W n
q
/GS0 gs
563.25 0 0 -75 64.5 820.5 cm
/Im0 Do
Q
Q
BT
/CS2 cs 0.427 0.431 0.439 scn
/TT0 1 Tf
-0.028 Tw 12 0 0 12 64.5 720 Tm
[(Posterdiskussion)-39( -)-42( Supportivtherapie,)-40( Infektionen)-41( )]TJ
/CS0 cs 0 scn
/TT1 1 Tf
0 Tw /Span<>> BDC
0 -1.187 TD
( )Tj
EMC
0.03 Tw 9.75 0 0 9.75 64.5 690.75 Tm
[(P949)-50( -)-52( Prophylaxis)-63( of)-12( chemotherapy)-49(-)-52(induced)-36( neutropenia)-27( with)-68( Lipegfilgrastim)-16( in)-68( patients)-36( with)-68( lung)-33( cancer:)-29( results)-55( from an)]TJ
0 -1.231 TD
[(interim)-77( analysis)-3( of)-12( the)-72( non)-24(-)-52(interventional)-53( study)-71( NADIR)]TJ
0 Tw /Span<>> BDC
T*
( )Tj
EMC
/TT2 1 Tf
0.03 Tw 0 -1.846 TD
[(Potthoff)-14( K.)]TJ
ET
/CS0 CS 0 SCN
0.75 w
q 1 0 0 1 64.5 648 cm
0 0 m
46.5 0 l
S
Q
BT
/TT2 1 Tf
0 Tw 8.25 0 0 8.25 111 652.5 Tm
(1)Tj
0.03 Tw 9.75 0 0 9.75 116.25 648.75 Tm
[(,)-30( L\374ck)-42( A.)]TJ
0 Tw 8.25 0 0 8.25 156 652.5 Tm
(2)Tj
0.03 Tw 9.75 0 0 9.75 161.25 648.75 Tm
[(,)-30( Frost)-30( N.)]TJ
0 Tw 8.25 0 0 8.25 202.5 652.5 Tm
(3)Tj
0.03 Tw 9.75 0 0 9.75 207.75 648.75 Tm
[(,)-30( Losem)-76( C.)]TJ
0 Tw 8.25 0 0 8.25 256.5 652.5 Tm
(4)Tj
0.03 Tw 9.75 0 0 9.75 261.75 648.75 Tm
[(,)-30( Weide)-12( R.)]TJ
0 Tw 8.25 0 0 8.25 308.25 652.5 Tm
(5)Tj
0.03 Tw 9.75 0 0 9.75 313.5 648.75 Tm
[(,)-30( Schulz)-76( H.)]TJ
0 Tw 8.25 0 0 8.25 362.25 652.5 Tm
(6)Tj
/Span<>> BDC
9.75 0 0 9.75 64.5 636.75 Tm
( )Tj
EMC
/TT1 1 Tf
8.25 0 0 8.25 64.5 622.5 Tm
(1)Tj
0.03 Tw 9.75 0 0 9.75 69.75 618.75 Tm
[(iOMEDICO AG,)-46( Freiburg,)-76( Germany,)-72( )]TJ
0 Tw 8.25 0 0 8.25 231 622.5 Tm
(2)Tj
0.03 Tw 9.75 0 0 9.75 236.25 618.75 Tm
[(Zentrum)-46( f\374r)-64( Urologie)-46( und)-24( Onkologie,)-66( Rostock,)-33( Germany,)-72( )]TJ
0 Tw 8.25 0 0 8.25 488.25 622.5 Tm
(3)Tj
0.03 Tw 9.75 0 0 9.75 493.5 618.75 Tm
[(Charit\351)-8( Campus)-46( Virchow)-59(-)]TJ
-44 -1.538 Td
[(Klinikum,)-21( Berlin,)-12( Germany,)-71( )]TJ
0 Tw 8.25 0 0 8.25 184.5 607.5 Tm
(4)Tj
0.03 Tw 9.75 0 0 9.75 189.75 603.75 Tm
[(Praxis)-68( f\374r)-64( Onkologie)-36( und)-24( H\344matologie,)-32( Neuss,)-42( Germany,)-71( )]TJ
0 Tw 8.25 0 0 8.25 443.25 607.5 Tm
(5)Tj
0.03 Tw 9.75 0 0 9.75 448.5 603.75 Tm
[(Praxisklinik)-77( f\374r)-64( H\344matologie)-2( und)]TJ
-39.385 -1.538 Td
[(Onkologie)-36( Koblenz,)-32( Koblenz,)-32( Germany,)-71( )]TJ
0 Tw 8.25 0 0 8.25 240.75 592.5 Tm
(6)Tj
0.03 Tw 9.75 0 0 9.75 246 588.75 Tm
[(Praxis)-68( Internistischer)-7( Onkologie)-36( und)-24( H\344matologie)-2( \(PIOH\),)-73( Frechen,)-54( Germany)]TJ
0 Tw /Span<>> BDC
-18.615 -1.231 Td
( )Tj
EMC
/TT0 1 Tf
0 -1.538 TD
[(Introduction:)-65( )]TJ
/TT1 1 Tf
0.03 Tw 6.538 0 Td
[(Platinum)-33(-)-52(based)-45( chemotherapy)-49( regimens)-42( are)-16( the)-71( standard)-32( treatment)-7( for)-64( patients)-36( with)-68( lung)-33( cancer.)-29( Neutropenia)]TJ
-6.538 -1.231 Td
[(is)-47( one)-24( of)-12( the)-71( most)-64( serious)-8( hematological)-62( and)-24( major)-38( dose)-63(-)-52(limiting)-43( toxicities)-12( that)-24( can)-3( comprise)-21( treatment)-7( outcomes.)-2( Guidelines)]TJ
0 -1.231 TD
[(recommend)-29( prophylactic)-50( granulocyte)-62( colony)-33(-)-52(stimulating)-67( factor)-37( \(G)-43(-)-52(CSF\))-52( use)-3( for)-64( patients)-36( \(pts\) at)-12( high)-33( risk)-60( for)-64( febrile)]TJ
T*
[(neutropenia)-27( \(FN\).)-31( Lipegfilgrastim)-15( \(LIP\))-64( is)-47( a)-59( glyco)-51(-)-52(pegylated)-49( G)-68(-)-52(CSF approved)-62( to)-12( reduce)-20( the)-71( duration)-2( of)-12( neutropenia)-27( and)-24( the)]TJ
T*
[(incidence)-7( of)-12( FN.)-4( Here)-64( we)-30( report)-3( on)-42( results)-55( from an)-42( interim)-77( analysis)-3( of)-12( the)-72( non)-24(-)-52(interventional)-53( study)-71( NADIR)-43( in)-68( pts)-51( with)-68( lung)]TJ
0 Tw T*
(cancer.)Tj
/TT0 1 Tf
T*
[(Methods:)-17( )]TJ
/TT1 1 Tf
0.03 Tw 4.769 0 Td
[(The)-46( prospective)-41( multicenter)-33( non)-24(-)-52(interventional)-53( study)-72( NADIR)-43( is)-47( conducted)-1( in)-68( 270)-24( outpatient)-69( centers)-29( and)-24( hospitals)]TJ
-4.769 -1.231 Td
[(across)-55( Germany,)-71( aiming)-55( to)-12( collect)-12( data)-54( on)-42( prophylactic)-50( LIP)-37( use)-3( in)-68( 2500)-7( pts)-51( with)-68( different)-2( tumor)-59( entities)-63( under)-58( antineoplastic)]TJ
0 -1.231 TD
[(treatment)-7( in)-68( routine)-20( clinical)-77( practice.)-67( The)-46( objective)-54( of)-12( the)-72( study)-71( is)-47( to)-12( assess)-42( the)-72( effectiveness)-10( of)-12( LIP)-37( by)-21( determining)-7( the)]TJ
0 -1.231 TD
[(incidence)-7( of)-12( neutropenia)-27( grade)-58( 3/4)-71( and)-24( FN.)]TJ
/TT0 1 Tf
0 Tw T*
[(Results:)-55( )]TJ
/TT1 1 Tf
0.03 Tw 4.308 0 Td
[(At)-55( the)-71( time)-34( of)-12( data)-54( cut)-51(-)-52(off)-42( \(3/2016\),)-75( 2422)-7( pts)-51( were)-64( enrolled)-58( by)-21( 198)-24( sites.)-51( 1556)-7( pts)-51( were)-64( evaluable,)-57( thereof)-41( 172)-24( pts)]TJ
-4.308 -1.231 Td
[(with)-68( lung)-33( cancer)-76( \(NSCLC:)-77( 73;)-72( SCLC:)-55( 94\).)-46( Mean)-37( age)-24( was)-68( 65.1)-54( years)-16( for)-64( lung)-33( cancer)-76( pts,)-3( 56.4%)-11( of)-12( pts)-51( were)-64( male.)-17( At)-55( inclusion)]TJ
T*
[(68.0%)-11( of)-12( pts)-51( had)-24( an)-42( ECOG)-55( of)-12( 0)-59( or)-34( 1)-59( \(14.5%)-63( missing)-72( data\).)-58( In)-12( 79.1%)-11( of)-12( pts)-51( chemotherapy)-49( was)-68( applied)-7( in)-68( a)-59( palliative)-33( setting.)]TJ
T*
[(78.5%)-11( of)-12( pts)-51( were)-64( treated)-41( with)-68( platinum)-67(-)-52(based)-45( combination)-71( chemotherapy.)-1( 589)-24( of)-12( 636)-24( documented)-35( chemotherapy)-49( cycles)]TJ
T*
[(\(92.6%\))-37( were)-64( supported)-14( by)-21( LIP.)-67( Neutropenia)-14( grade)-58( 3/4)-72( occurred)-33( in)-68( 33.1%)-11( of)-12( pts,)-3( one)-24( patient)-75( developed)-1( FN.)-4( Dose)-51( reductions)]TJ
T*
[(were)-64( reported)-45( in)-68( 73)-42( of)-12( 636)-24( cycles)-68( \(11.4%\),)-67( in)-68( 10)-42( cases)-3( due)-24( to)-12( chemotherapy)-49(-)-52(induced)-36( neutropenia.)-56( For)-38( 12.2%)-11( of)-12( pts)-51( LIP)-37(-)]TJ
T*
[(related)-20( adverse)-58( events)-54( were)-64( reported.)-75( The)-46( most)-64( frequent)-23( LIP)-37(-)-52(related)-20( adverse)-58( event)-16( reported)-45( was)-68( leucocytosis)-16( \(3.5%\).)-8( LIP)-37(-)]TJ
T*
[(related)-20( serious)-8( adverse)-58( events)-54( were)-64( reported)-45( for)-64( 1.7%)-29( of)-12( pts.)]TJ
/TT0 1 Tf
0 Tw T*
[(Conclusions:)-51( )]TJ
/TT1 1 Tf
0.03 Tw 6.692 0 Td
[(In)-12( pts)-51( with)-68( lung)-33( cancer)-76( treated)-41( with)-68( a)-59( platinum)-67(-)-52(based)-45( combination)-71( regimen)-3( LIP)-37( was)-68( effective)-45( and)-24( well)]TJ
-6.692 -1.231 Td
[(tolerated.)-62( The)-46( incidence)-7( of)-12( neutropenia)-27( grade)-58( 3/4)-71( and)-24( FN)-52( was)-68( low)-38( and)-24( comparable)-7( to)-12( literature.)-63( FN)-52( only)-12( occurred)-33( in)-68( <)-31( 1%)-17( of)]TJ
0 Tw T*
[(pts.)-3( )]TJ
/Span<>> BDC
0 -1.231 TD
( )Tj
EMC
0.03 Tw 0 -1.538 TD
[(Disclosure:)-55( No)-30( conflict)-42( of)-12( interest)-29( disclosed.)]TJ
0 Tw /Span<>> BDC
0 -1.231 TD
( )Tj
EMC
0.03 Tw 0 -2.846 TD
[(Angaben)-74( f\374r)-64( Zitate:)]TJ
ET
q 1 0 0 1 64.5 254.25 cm
0 0 m
85.5 0 l
S
Q
BT
/TT1 1 Tf
9.75 0 0 9.75 64.5 243 Tm
[(-)-52( Titel)-34( des)-3( Abstracts,)-16( siehe)-71( oben)]TJ
0 -1.231 TD
[(-)-52( Namen)-8( der)-16( Autoren,)-66( siehe)-71( oben)]TJ
T*
[(-)-52( Abstract)-24(-)-52(Nr.,)-4( siehe)-72( oben)]TJ
T*
[(-)-52( Quelle:)-63( Abstract)-24(-)-52(USB)-21(-)-52(Stick)-64( Jahrestagung)-18( der)-16( Deutschen,)-19( \326sterreichischen)-36( und)-24( Schweizerischen)-36( Gesellschaften)-1( f\374r)]TJ
T*
[(H\344matologie)-2( und)-24( Medizinische)-67( Onkologie)-36( 2016)]TJ
T*
[(-)-52( ISSN)-51( 1863)-7(-)-52(1819)]TJ
0.022 Tw 7.5 0 0 7.5 80.25 158.25 Tm
[(USB)-44(-)-67(Stick)-33( erstellt)-55( von:)-10( )]TJ
[(pharma)-10( service)]TJ
ET
q 1 0 0 1 159 157.5 cm
0 0 m
51.75 0 l
S
Q
BT
/TT1 1 Tf
7.5 0 0 7.5 210.75 158.25 Tm
[( -)-67( eine)-10( Business)-43( Unit)-22( der)-55( documediaS)-42( GmbH)-11( \225)-50( Hannover,)-87( Germany)-88( \225)-50( )]TJ
0 Tw (www.pharmaservice.de)Tj
ET
q 1 0 0 1 447 157.5 cm
0 0 m
78 0 l
S
Q
BT
/TT1 1 Tf
0.022 Tw 7.5 0 0 7.5 525 158.25 Tm
[( \225)-50( +49)]TJ
/Span<>> BDC
2.7 0 Td
( )Tj
EMC
(\(0\))Tj
/Span<>> BDC
1.6 0 Td
( )Tj
EMC
(511)Tj
/Span<>> BDC
2 0 Td
( )Tj
EMC
(54)Tj
/Span<>> BDC
1.5 0 Td
( )Tj
EMC
(276)Tj
/Span<>> BDC
2 0 Td
( )Tj
EMC
(0)Tj
ET
endstream
endobj
13 0 obj
<>
endobj
14 0 obj
(koVeJmT\r)
endobj
22 0 obj
<>stream
Adobe d
'$''''$25552;;;;;;;;;;
%%#(((((#,0000,7;;;7;;;;;;;;;;
%%#(((((#,0000,7;;;7;;;;;;;;;; d "
w !1Aa"Q2BqR
35STs#$%&'()*46789:CDEFGHIJUVWXYZbcdefghijrtuvwxyz !"1AQa#2B
$%&'()*3456789:CDEFGHIJRSTUVWXYZbcdefghijqrstuvwxyz ? V Qaݾ,p1c |ku@q,K:E
9T&Q J{-H۳Ln8=V^*Ѣҳ8gDg<eT&ӯS%%c#ǒ{ZgwqCgtqtc2D#'jdUz0"z=|f ^o_*ɤ&=Ǜ2 ygT{e/PI'VXyT-/T-#J=αaii̛#CF; 6}~Rm"P3ȥ-O ,ٗ|ug_h M[\5B6ag3`kg3J+QWƭgm)BՀ!T2Xd A
JuhuqGpy2۲r9Vv[H-n['
soc$#8'YDլ¨\^$[!g+f0,XP:=\gPY$0QA;6<1U$cӨ=ΐR2]vmB69Vk9B vv|-OՎ %> :ϕ=U#Y$X$^%A!MyH5N YU;UՒ@B}҄FhfyC:,b㟙#=}i4$yRr{0 Q9 yg=E(3\ U]66oo/haS#{mIOoyIcTIR默3X*@aa3haخ3\;wuuo$[EHP YγyFEvD&8 >>uJ20\mbXiU
鹣5xCR.58on'☴rJXj]*O+,rA88F{iRDO
-}IaMa